Aquoral Expands Access in Sleep Medicine Through New Partnership With MVAP Medical Supplies

Prescription dry-mouth treatment now available for purchase through the MVAP Medical Supplies catalog



PHOENIX, AZ, UNITED STATES, September 16, 2026 / EINPresswire.com/ -- SCOTTSDALE, Ariz., [September 10, 2026] — K Pharmaceuticals today announced a new distribution partnership with MVAP Medical Supplies, Inc., making Aquoral® Protective Oral Spray available for purchase through the MVAP Medical Supplies catalog.

The partnership expands access to Aquoral within the sleep and respiratory care community, where dry mouth (clinically known as xerostomia) is a common but frequently overlooked challenge. For patients using positive airway pressure (PAP) therapy, chronic mouth breathing, medications and other comorbidities can all contribute to persistent oral dryness and discomfort.

MVAP Medical Supplies provides products across sleep diagnostics, home sleep testing, respiratory care and CPAP/patient care, making the addition of Aquoral a natural fit within the company's existing sleep-health portfolio.

“For us, this is about making Aquoral easier to access through the channels sleep professionals already know and use,” said Bennett Blakeman, CEO of K Pharmaceuticals. “Dry mouth can have a meaningful impact on patient comfort with PAP therapy. MVAP already serves the professionals caring for these patients every day, which makes this relationship an exciting step forward for Aquoral.”

“We work with sleep labs, hospitals, and healthcare facilities nationwide, and that kind of reach is what makes this partnership worthwhile,” said Brent Mjoen, COO of MVAP Medical Supplies. “Bringing Aquoral into our catalog means facilities all over the country now have easy access to a prescription option for dry mouth, right alongside everything else they already order from us. When you can put a solution like this in front of that many providers at once, it’s a meaningful step for patient access.”

A Common Problem That Is Often Missed

Dry mouth is frequently reported among patients with obstructive sleep apnea and those using CPAP therapy. A prospective study found morning xerostomia in 45% of people with sleep apnea compared with 20.4% of controls. Among study participants using CPAP, 57.1% reported dry mouth upon waking.

Despite how common the condition is, the clinical term “xerostomia” may not be familiar to every patient or healthcare professional. For that reason, Aquoral and K Pharmaceuticals emphasize the plain-language term dry mouth in education and communication, while recognizing xerostomia as the clinical name for the condition.

Persistent dry mouth can interfere with sleep, speaking, eating and swallowing, while also increasing the risk of tooth decay, oral fungal infections and other oral-health complications. In sleep medicine, those symptoms can add another layer of discomfort for patients already adapting to PAP or oral-appliance therapy.

A Prescription, Lipid-Based Approach

Aquoral is an FDA-cleared, prescription Class II medical device indicated for the relief of chronic and temporary dry mouth, clinically known as xerostomia. Aquoral uses oxygenated glycerol triester (OGT) technology designed to spread across the oral mucosa and create a protective lipid film that provides sustained lubrication.

Unlike traditional water-based saliva substitutes that may be rapidly diluted or swallowed, Aquoral’s lipid-based formulation is designed to remain on the oral tissues longer and provide extended relief.

Expanding Access Through the Sleep-Care Channel

By adding Aquoral to its catalog, MVAP gives sleep labs, respiratory providers and other healthcare organizations that already purchase through MVAP another pathway to access a prescription option for patients experiencing persistent dry mouth.

Peter Allen, BSRC, RRT, NPS, SDS, RST, RPSGT, FAAST, National Clinical Specialist for Aquoral, said he is especially excited about the partnership given his nearly 30-year working relationship with MVAP. He sees the addition of Aquoral to the MVAP catalog as a meaningful way to broaden access to a prescription option for dry mouth across the sleep-care community.

Aquoral is now available for purchase through MVAP Medical Supplies.

About Aquoral

Aquoral® Protective Oral Spray is an FDA-cleared, prescription Class II medical device indicated for the relief of chronic and temporary dry mouth (xerostomia). Aquoral utilizes oxygenated glycerol triester technology to create a protective lipid barrier across the oral mucosa, providing sustained lubrication for patients experiencing oral dryness. For more information, visit www.aquoralspray.com.

About MVAP Medical Supplies, Inc.

MVAP Medical Supplies, Inc., based in Thousand Oaks, California, provides supplies and products across sleep, EEG, EMG, IOM, respiratory and patient care. Its offerings include sleep diagnostic supplies, home sleep testing products, respiratory products, CPAP supplies and patient-care products. For more information, visit www.mvapmed.com.

Bennett Blakeman
K Pharmaceuticals LLC
+1 855-922-9913
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook

This press release can be viewed online at: https://www.einpresswire.com/article/941264717

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.
© 1995-2026 Newsmatics Inc. All Right Reserved.